Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obecabtagene Autoleucel as Consolidation in High-risk B-cell ALL
NCT07053059Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2025
- Primary completion
- May 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of obecabtagene autoleucel in acute lymphoblastic leukemia (ALL), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2025; status: recruiting.
02
Drugs
obecabtagene autoleucel
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07053059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07053059.